327 related articles for article (PubMed ID: 28870104)
21. Influenza virus resistance to antiviral therapy.
van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
[TBL] [Abstract][Full Text] [Related]
22. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
Front Immunol; 2019; 10():531. PubMed ID: 30941148
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828).
Xie Y; Song W; Xiao W; Gu C; Xu W
Expert Opin Ther Pat; 2013 Nov; 23(11):1517-24. PubMed ID: 23967861
[TBL] [Abstract][Full Text] [Related]
24. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.
Gasparini R; Amicizia D; Lai PL; Bragazzi NL; Panatto D
J Prev Med Hyg; 2014 Dec; 55(4):109-29. PubMed ID: 26137785
[TBL] [Abstract][Full Text] [Related]
25. Novel insights into proteolytic cleavage of influenza virus hemagglutinin.
Bertram S; Glowacka I; Steffen I; Kühl A; Pöhlmann S
Rev Med Virol; 2010 Sep; 20(5):298-310. PubMed ID: 20629046
[TBL] [Abstract][Full Text] [Related]
26. Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication.
Okumura Y; Takahashi E; Yano M; Ohuchi M; Daidoji T; Nakaya T; Böttcher E; Garten W; Klenk HD; Kido H
J Virol; 2010 May; 84(10):5089-96. PubMed ID: 20219906
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.
Wang J; Li F; Ma C
Biopolymers; 2015 Jul; 104(4):291-309. PubMed ID: 25663018
[TBL] [Abstract][Full Text] [Related]
28. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.
Leu CH; Yang ML; Chung NH; Huang YJ; Su YC; Chen YC; Lin CC; Shieh GS; Chang MY; Wang SW; Chang Y; Chao J; Chao L; Wu CL; Shiau AL
Antimicrob Agents Chemother; 2015 Sep; 59(9):5619-30. PubMed ID: 26149981
[TBL] [Abstract][Full Text] [Related]
29. Influenza chemotherapy: a review of the present state of art and of new drugs in development.
Lüscher-Mattli M
Arch Virol; 2000; 145(11):2233-48. PubMed ID: 11205114
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
[TBL] [Abstract][Full Text] [Related]
31. Approaches and strategies for the treatment of influenza virus infections.
Colacino JM; Staschke KA; Laver WG
Antivir Chem Chemother; 1999 Jul; 10(4):155-85. PubMed ID: 10480736
[TBL] [Abstract][Full Text] [Related]
32. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition.
Böttcher E; Freuer C; Steinmetzer T; Klenk HD; Garten W
Vaccine; 2009 Oct; 27(45):6324-9. PubMed ID: 19840668
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2013 Apr; 8(4):411-26. PubMed ID: 23373617
[TBL] [Abstract][Full Text] [Related]
34. New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections.
van de Wakker SI; Fischer MJE; Oosting RS
Eur J Pharmacol; 2017 Aug; 809():178-190. PubMed ID: 28533172
[TBL] [Abstract][Full Text] [Related]
35. Clinical Implications of Antiviral Resistance in Influenza.
Li TC; Chan MC; Lee N
Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
[TBL] [Abstract][Full Text] [Related]
36. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Nguyen HT; Fry AM; Gubareva LV
Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
[TBL] [Abstract][Full Text] [Related]
37. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus.
Zhirnov OP; Matrosovich TY; Matrosovich MN; Klenk HD
Antivir Chem Chemother; 2011 Mar; 21(4):169-74. PubMed ID: 21602614
[TBL] [Abstract][Full Text] [Related]
38. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.
Pozo F; Lina B; Andrade HR; Enouf V; Kossyvakis A; Broberg E; Daniels R; Lackenby A; Meijer A;
J Clin Virol; 2013 May; 57(1):5-12. PubMed ID: 23375738
[TBL] [Abstract][Full Text] [Related]
39. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
40. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK; Tsai CH; Shie JJ; Fang JM
Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
